Date & Location
Thursday, December 8, 2016 7:00 AM - Friday, December 9, 2016 4:00 PM
Zuckerman Research Center 417 E 68th St, New York,
Family Medicine, Internal Medicine , Medical Oncology, Nurse Practitioner, Nursing, Physicians Assistant, Radiation Oncology, Radiology-Diagnostic, Radiology-Interventional, Research Fellow, Urology
The course will include coverage of the following topics:
- Comparing outcomes for surgery and radiotherapy in clinically localized prostate cancer
- Optimal management strategies to treat acute and late side effects of radiotherapy
- Tips for reducing errors and improving QA for prostate Brachytherapy
- Updates on SBRT and Proton therapy in the treatment of prostate cancer
- Salvage radiotherapy after primary treatment failures and expected toxicity outcomes
- Optimal integration of hormonal therapy with prostate radiotherapy
- New developments in External Beam Treatment Planning including MR-Treatment Planning
- Guidelines for the Radiation Oncologist contouring target and nodal regions
- Integrating imaging into treatment selection and treatment
Call for Abstracts
Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. The deadline for abstract submissions is November 15, 2016. Please click on the Abstracts link above to learn more, or to submit an abstract.
Memorial Sloan Kettering gratefully acknowledges the following organizations for providing educational grants or financial support for this live activity:
- Augmenix, Inc.
- Best Medical International, Inc.
- Theragenics Corporation®
- Varian Medical Systems
At the conclusion of this activity participants will be able to:
- Understand the advantages and disadvantages of a radiotherapeutic approach compared to surgery in the treatment of clinically localized prostate cancer.
- To provide information to the audience regarding optimal management of treatment related side effects after radiotherapy.
- To familiarize the audience with new developments in treatment planning for EBRT and brachytherapy in the treatment of prostate cancer.
- To highlight important advances in SBRT and Proton therapy in the treatment of prostate as well as discuss anticipated side effects of tumor control outcomes with these modalities.
- To discuss the role of salvage radiotherapy after primary treatment failures and expected toxicity outcomes.
|MDs, PhDs, DOs, and Medical Physicists
|MSK Alliance and MSK Alumni
|Residents, Fellows, RNs, Medical Students and other Healthcare Providers
Industry Members - Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.
MSK Alliance Members - If you are a MSK Alliance member, please email us at email@example.com with your affiliation for discount information.
If you cancel your participation in this course, your registration fee, less a $75 administrative fee, will be refunded when email notification is received by the MSK Office of Continuing Medical Education (MSK CME) at least 7 days prior to the first day of the course (firstname.lastname@example.org).Cancellations or no-shows after this date are not eligible for a refund. MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, we will refund the registration fee in full, but are not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies. At any time, you may substitute another registrant in your place after contacting MSK CME with the relevant information.
Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement
Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.